BlueCrest Capital Management’s Quest Diagnostics DGX Stock Holding History

BlueCrest Capital Management’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-5,574	Closed	-$601K	–	992
2018 Q3	$601K	Sell	5,574 -27,144	-83%	-$2.98M	0.02%	653
2018 Q2	$3.6M	Buy	32,718 +27,525	+530%	+$2.87M	0.09%	212
2018 Q1	$521K	Sell	5,193 -5,330	-51%	-$546K	0.02%	753
2017 Q4	$1.04M	Buy	+10,523	New	+$998K	0.03%	372
2017 Q3	–	Sell	-3,048	Closed	-$339K	–	892
2017 Q2	$339K	Buy	3,048 +853	+39%	+$90.2K	0.01%	668
2017 Q1	$216K	Buy	+2,195	New	+$209K	0.01%	606
2016 Q1	–	Sell	-8,911	Closed	-$634K	–	849
2015 Q4	$634K	Buy	8,911 +4,157	+87%	+$279K	0.03%	518
2015 Q3	$292K	Sell	4,754 -3,699	-44%	-$259K	0.01%	713
2015 Q2	$613K	Buy	+8,453	New	+$624K	0.02%	585
2015 Q1	–	Sell	-11,824	Closed	-$793K	–	640
2014 Q4	$793K	Buy	+11,824	New	+$746K	0.03%	399

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

FMI

Fiduciary Management Inc Milwaukee, Wisconsin $7.03B AUM 11.68% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BlueCrest Capital Management's DGX Position: Q4 2018 in Review

BlueCrest Capital Management sold out of Quest Diagnostics (DGX) in Q4 2018, closing a stake of 5,574 shares — an estimated $601K sold.

BlueCrest Capital Management first reported a position in DGX in Q4 2014 and held it in 10 quarters. The position peaked at $3.6M in Q2 2018. 625 funds tracked by Wall St. Rank hold DGX as of Q4 2018.

BlueCrest Capital Management reported no remaining Quest Diagnostics position as of Q4 2018 after selling out during the quarter.
BlueCrest Capital Management sold 5,574 Quest Diagnostics shares in Q4 2018, an estimated $601K.
BlueCrest Capital Management first reported a position in Quest Diagnostics in Q4 2014 and held it in 10 quarters.
BlueCrest Capital Management's Quest Diagnostics position peaked at $3.6M in Q2 2018.
625 funds tracked by Wall St. Rank held Quest Diagnostics as of Q4 2018.

Based on BlueCrest Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.